Literature DB >> 21531765

High-throughput RNAi screening reveals novel regulators of telomerase.

Maria Antonietta Cerone1, Darren J Burgess, Cristina Naceur-Lombardelli, Christopher J Lord, Alan Ashworth.   

Abstract

Telomerase is considered an attractive anticancer target on the basis of its common and specific activation in most human cancers. While direct telomerase inhibition is being explored as a therapeutic strategy, alternative strategies to target regulators of telomerase that could disrupt telomere maintenance and cancer cell proliferation are not yet available. Here, we report the findings of a high-throughput functional RNA interference screen to globally profile the contribution of kinases to telomerase activity (TA). This analysis identified a number of novel telomerase modulators, including ERK8 kinase, whose inhibition reduces TA and elicited characteristics of telomere dysfunction. Given that kinases represent attractive drug targets, we addressed the therapeutic implications of our findings, such as demonstrating how limiting TA via kinase blockade could sensitize cells to inhibition of the telomere-associated protein tankyrase. Taken together, our findings suggest novel combinatorial approaches to targeting telomere maintenance as a strategy for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21531765     DOI: 10.1158/0008-5472.CAN-10-2734

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.

Authors:  Ozlem Kulak; Hua Chen; Brody Holohan; Xiaofeng Wu; Huawei He; Dominika Borek; Zbyszek Otwinowski; Kiyoshi Yamaguchi; Lauren A Garofalo; Zhiqiang Ma; Woodring Wright; Chuo Chen; Jerry W Shay; Xuewu Zhang; Lawrence Lum
Journal:  Mol Cell Biol       Date:  2015-05-04       Impact factor: 4.272

2.  Nek7 Protects Telomeres from Oxidative DNA Damage by Phosphorylation and Stabilization of TRF1.

Authors:  Rong Tan; Satoshi Nakajima; Qun Wang; Hongxiang Sun; Jing Xue; Jian Wu; Sabine Hellwig; Xuemei Zeng; Nathan A Yates; Thomas E Smithgall; Ming Lei; Yu Jiang; Arthur S Levine; Bing Su; Li Lan
Journal:  Mol Cell       Date:  2017-02-16       Impact factor: 17.970

3.  MAPK15 is part of the ULK complex and controls its activity to regulate early phases of the autophagic process.

Authors:  David Colecchia; Francesca Dapporto; Serena Tronnolone; Laura Salvini; Mario Chiariello
Journal:  J Biol Chem       Date:  2018-08-21       Impact factor: 5.157

4.  Arena3D: visualizing time-driven phenotypic differences in biological systems.

Authors:  Maria Secrier; Georgios A Pavlopoulos; Jan Aerts; Reinhard Schneider
Journal:  BMC Bioinformatics       Date:  2012-03-22       Impact factor: 3.169

5.  ERK8 is a negative regulator of O-GalNAc glycosylation and cell migration.

Authors:  Joanne Chia; Keit Min Tham; David James Gill; Emilie Anne Bard-Chapeau; Frederic A Bard
Journal:  Elife       Date:  2014-03-11       Impact factor: 8.140

6.  MAPK15 mediates BCR-ABL1-induced autophagy and regulates oncogene-dependent cell proliferation and tumor formation.

Authors:  David Colecchia; Matteo Rossi; Federica Sasdelli; Sveva Sanzone; Angela Strambi; Mario Chiariello
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

Review 7.  Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.

Authors:  Jenna L Riffell; Christopher J Lord; Alan Ashworth
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

8.  MAPK15/ERK8 stimulates autophagy by interacting with LC3 and GABARAP proteins.

Authors:  David Colecchia; Angela Strambi; Sveva Sanzone; Carlo Iavarone; Matteo Rossi; Claudia Dall'Armi; Federica Piccioni; Arturo Verrotti di Pianella; Mario Chiariello
Journal:  Autophagy       Date:  2012-09-04       Impact factor: 16.016

9.  Structure prediction and validation of the ERK8 kinase domain.

Authors:  Angela Strambi; Mattia Mori; Matteo Rossi; David Colecchia; Fabrizio Manetti; Francesca Carlomagno; Maurizio Botta; Mario Chiariello
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

10.  Loss of telomere protection: consequences and opportunities.

Authors:  Jacqueline J L Jacobs
Journal:  Front Oncol       Date:  2013-04-15       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.